GlobeNewswire News Room·2025-06-01 11:55Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, due to misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Organon provided positive statements while concealing material adverse facts about its priorities, particularly regarding capital allocation and a significant reduction in quarterly dividends [5]. - Following the acquisition of Dermavant, Organon prioritized debt reduction, leading to a 70% decrease in the regular quarterly dividend, which was not disclosed to investors [5]. Group 2: Participation Information - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].